Genenta Science (GNTA) Expected to Announce Earnings on Friday

Genenta Science (NASDAQ:GNTA) is projected to release its results before the market opens on Friday, March 27th. Analysts expect Genenta Science to post earnings of ($0.3641) per share for the quarter.

Genenta Science Stock Down 9.4%

Shares of GNTA stock opened at $0.63 on Friday. The stock has a 50-day moving average of $1.03 and a 200-day moving average of $1.98. Genenta Science has a one year low of $0.61 and a one year high of $10.00.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genenta Science presently has an average rating of “Sell”.

Hedge Funds Weigh In On Genenta Science

A number of large investors have recently modified their holdings of the business. Ghisallo Capital Management LLC bought a new position in shares of Genenta Science in the 4th quarter valued at about $482,000. Weiss Asset Management LP bought a new stake in Genenta Science during the fourth quarter worth about $480,000. Norges Bank bought a new stake in Genenta Science during the fourth quarter worth about $337,000. Alyeska Investment Group L.P. acquired a new position in Genenta Science during the fourth quarter valued at approximately $328,000. Finally, SmartHarvest Portfolios LLC acquired a new position in Genenta Science during the fourth quarter valued at approximately $26,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.